Immunopharmacological actions of the new antiallergic drug butyl 3'-(1H-tetrazol-5-yl)oxanilate. 3rd communication: inhibitory effects on histamine release from lung fragments, Schultz-Dale reaction in isolated tracheal muscle and experimental asthma in guinea pigs.
The inhibitory effects of butyl 3'-(1H-tetrazol-5-yl) oxanilate (WP-833), a new antiallergic drug, on histamine release from lung fragments, Schultz-Dale (SD) reaction in isolated tracheal muscle and experimental asthma were investigated in guinea pigs passively sensitized with homologous immunoglobulin E (IgE) serum. WP-833 dose-dependently inhibited antigen-induced histamine release from lung fragments. In addition, synergism as to inhibition of histamine release was observed with a combination of WP-833 and isoprenaline but not with that of WP-833 and theophylline. WP-833 also inhibited antigen-mediated SD reaction of isolated tracheal muscle without showing antagonistic actions upon histamine- and leukotriene D4-induced contraction of normal tracheal muscle. Experimental asthma was clearly inhibited in a dose-dependent fashion by oral administration of WP-833.
D000818:Animals; D001249:Asthma / Q000276:immunology / Q000378:metabolism*; D001393:Azoles / Q000494:pharmacology*; D004140:Dinitrophenols / Q000276:immunology; D006168:Guinea Pigs; D006636:Histamine Release / Q000187:drug effects*; D008168:Lung / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D013189:SRS-A / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology*; D014132:Trachea / Q000187:drug effects / Q000378:metabolism*
D001393:Azoles; D004140:Dinitrophenols; D013189:SRS-A; D013777:Tetrazoles; C036097:butyl 3-(1H-tetrazol-5-yl)oxanilate